Luteal phase

ŌURA Announces Be the Expert in You Campaign to Promote Body Literacy for Women

Retrieved on: 
Wednesday, May 1, 2024
Wearables, Mobile Technology, Technology, Women, Fitness & Nutrition, Biotechnology, Hardware, Health, Consumer, General Health, Flo, FDA, Clue, University, Menstrual cycle, Pregnancy, Hot, Hope, Motivation, Male, Natural Cycles, Partnership, Conference, Research, Human, Heart rate, Female, Physiology, Vogue, Expert, Luteal phase, Oura Health, Menopause, Multimedia, Migraine, Temperature, HRV, Algorithm, Organization, Sleep, Nursing

“For example, a recent survey found that one in four women do not understand their menstrual cycle.

Key Points: 
  • “For example, a recent survey found that one in four women do not understand their menstrual cycle.
  • The latest enhancement to Oura's period tracking feature, Cycle Insights , will provide members with even more details about their cycles.
  • Designing the Future of Wearable Tech for Women, by Women
    Oura is proud to have a strong group of women at the helm of these features, research studies, and partnerships.
  • Seeing my scores and Oura data has helped inform me what's happening to my body beyond my cycle.

Five ways to take control of your menstrual cycle and improve your sports performance

Retrieved on: 
Tuesday, September 5, 2023
Exercise, Yoga, Male, Fatigue, Ovulation, Food, Luteal phase, Diet, Sleep, Breast, Friends, Anxiety, Follicular phase, Woman, Vegetable, Fruit, Sleep hygiene, Pain, Athlete, Medicine, Sunlight, Man, Walking, Bleeding, Time, Water, Motivation, Pleasure, Miscarriage, Menstrual cycle, Sport, Mouse, Bloating, Progesterone, Health, Birth control, Nursing, Pharmaceutical industry, Menstruation

There are phases of the menstrual cycle, based upon hormonal fluctuations, where certain symptoms are more frequently experienced.

Key Points: 
  • There are phases of the menstrual cycle, based upon hormonal fluctuations, where certain symptoms are more frequently experienced.
  • A menstrual cycle should last between 21 and 35 days, with menstruation indicating day one of the cycle and the number of days until the next bleed.
  • It is during this time that the menstrual cycle is frequently associated with negative symptoms such as bloating, fatigue and changes in mood.
  • So taking a proactive approach can help to promote sports performance on every day of the menstrual cycle.

1. Track your cycle

    • Note the first day of your period to check you are having a regular cycle.
    • This helps to determine what’s caused by the menstrual cycle as opposed to other factors.
    • Everyone has a unique experience of the menstrual cycle and related symptoms.

2. Improve your diet and hydration

    • Eat a well-balanced diet, because this will help give you the energy for training and sport, while also reducing bloating and managing cravings.
    • If you train hard, ensure you are fuelling your training appropriately to support your menstrual cycle.
    • If you can, don’t eat too many processed foods such as takeaways, sugary drinks and crisps.

3. Get better sleep


    Sleep is vital because a lack of sleep or poor sleep quality can make many menstrual cycle-related symptoms worse. Sleep hygiene strategies can help prevent symptoms. These include going to bed and getting up at a similar time each day, starting the day with sunlight and limiting your caffeine intake (especially in the afternoon).

4. Reduce your stress


    Stress increases the severity and duration of symptoms related to the menstrual cycle and is therefore an important factor to manage. This is individual and finding a strategy that works for you will differ from person to person. Some ways to reduce stress could include socialising with friends, or meditating. Plan these in advance to prevent stress rather than reacting once you are already stressed.

5. Stay active

    • Consider other activities such as walking or yoga to manage symptoms like stomach cramps while you are implementing the above strategies.
    • And if there are days when you have more energy and motivation, maximise them while you are getting to understand your menstrual cycle.
    • Have these to hand if stomach cramps are affecting your ability to train around the time of menstruation.

Oova, Inc.'s Study Harnesses Hormone Data and Age to Precisely Determine Cycle Day within the Menstrual Cycle

Retrieved on: 
Thursday, August 3, 2023
Menstrual cycle, Pregnancy, Luteal phase, Obstetrics, Urine, Ovulation, IRMS, Follicular phase, LH, Woman, Research, Doctor of Philosophy, Luteinizing hormone, MD, Collection, PCOS, Patient, Gynaecology, Textbook, Key finding attacks, St. Barnabas' Hospital (Osaka), Massachusetts General Hospital, Female, Birth control, Medicina, MDPI

NEW YORK, Aug. 3, 2023  /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled "Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle." Conducted by esteemed scientists and co-authors, led by Dr. Amy Divaraniya, PhD founder of Oova, Inc., Dr. Mark B. Woodland, MD, Chair of Obstetrics and Gynecology at Tower Health, and Elinor Hills, content and brand lead at Oova, Inc, their discoveries bring a new understanding of the female reproductive cycle, particularly women with irregular periods, and confirms just how advanced and accurate remote hormone tracking has become.

Key Points: 
  • NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled " Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle ."
  • Adding to Oova's extensive collection of research and data on women's hormone levels, the study challenges the standard norms used for comparison and disproves the assumption of a 28-day reproductive cycle.
  • In this study, the Oova team evaluated hormone data from 4,123 cycles across 1,233 users, analyzing and tracking the LH and PdG via urine tests throughout menstrual cycles across different age groups.
  • Using Oova's hormone data to train their algorithm, Oova can now determine a woman's cycle day based on her age and hormone levels with 95% confidence.

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Retrieved on: 
Tuesday, July 11, 2023
IVR, Hot, Pregnancy, Luteal phase, System, IVF, Harvard Medical School, SAN, CEST, Preterm birth, Menopause, Hospital, Device, Administration, Massachusetts General Hospital, Massachusetts Institute of Technology, Birth control, Medical device, Woman

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.

Key Points: 
  • SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.
  • Dr. Friend’s presentation, entitled “Vaginal Rings: Expanding Drug Delivery Options for Women,” is scheduled for Wednesday, July 12th at 2:15 p.m. CEST.
  • The intravaginal ring (IVR) technology used in Daré’s clinical-stage product candidates, DARE-HRT1, a potential first-in-category product for treatment of vasomotor symptoms due to menopause designed to release bio-identical estradiol and bio-identical progesterone over 28 days, and DARE-FRT1/PTB1, potential first-in-category products for pregnancy maintenance, including the prevention of preterm birth (DARE-PTB1) and for luteal phase support as part of an IVF regimen (DARE-FRT1), designed to release bio-identical progesterone for up to 14 days, was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School.
  • The innovative IVR drug delivery technology is designed to release one or more active ingredients without the need for a membrane or reservoir to contain the active drug(s) or to control the release, allowing for sustained drug delivery and has the potential to result in products that offer women a number of benefits as compared to currently marketed products, including the opportunity to improve medication compliance, avoid first-pass metabolic side effects and deliver a better overall user experience.

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF FLO PMS COMPLETE

Retrieved on: 
Thursday, June 15, 2023
Poverty, Luteal phase, Education, Caffeine, Ovulation, Dysmenorrhea, Follicular phase, Woman, Cramp, Positiv, Political positivism, Gamer, Tablet, Mepyramine, Sibling, PMS, Menstruation, Patient, Bloating, Health, URO, Amazon, Skin, FLO, Fatigue, Maintenance (technical), Birth control, Pharmaceutical industry, Paracetamol, Capsule, MD

LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv, the women's health brand behind FLO, the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete. 

Key Points: 
  • LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv , the women's health brand behind FLO , the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete .
  • Since launching the FLO PMS Gummy in December 2018, O Positiv has positioned themselves as a premiere wellness brand with a range of products to address vaginal, digestive, skin, menstrual and menopausal health.
  • Each FLO PMS Complete tablet contains Acetaminophen, Caffeine and Pyrilamine Maleate to help alleviate menstrual and PMS related discomfort, such as cramps, aches, bloating, fatigue and water-related weight gain.
  • Now, with FLO Complete available, they can continue to use the trusted products of O Positiv for quick relief."

Endometriosis: how the condition may be linked to the immune system

Retrieved on: 
Saturday, April 15, 2023
Inflammation, Infection, Association, Pelvic pain, Pregnancy, Asthma, Luteal phase, Depression, Diabetes, Ovulation, Fever, COVID-19, Follicular phase, Woman, Infertility, Immunity, Research, COVID, Cell, Lupus, Uterus, Pain, Inflammatory bowel disease, Neoplasm, Autoimmune disease, Patient, Risk, Immune system, Menstrual cycle, Joint, Diagnosis, Chemokine, Bacteria, Cytokine, Chronic pain, Virus, Rheumatoid arthritis, Fatigue, Disease, Birth control, Vaccine, Pharmaceutical industry, Endometriosis

Despite how common endometriosis is, most women wait on average 7.5 years for a diagnosis in the UK.

Key Points: 
  • Despite how common endometriosis is, most women wait on average 7.5 years for a diagnosis in the UK.
  • Not only does this mean many years without treatment, it also puts them at risk of even greater health problems.
  • In the last few years, studies have found that the immune system is also affected by endometriosis.

Inflammation and immunity

    • To understand how our immune system and endometriosis are connected, it’s first important to understand an immune system process called inflammation.
    • The symptoms you experience as a result of inflammation will depend on the reason these cells have been mobilised.
    • If inflammation is caused by a virus, you might experience flu-like symptoms – such as a fever.
    • Most inflammation during the menstrual cycle happens in the uterus, but changes may also occur throughout the body.

Endometriosis and immunity

    • Research has also shown that people with endometriosis have disturbed immune cell function – namely a specific type of immune cell called natural killer cells.
    • These have a vital role in fighting viruses and tumours, but research shows they function more poorly in people with endometriosis.
    • The uterine lining in patients with endometriosis is also shown to produce excess molecules called chemokines that attract other immune cells, worsening inflammation.
    • Again, it’s still not certain whether altered immune function causes endometriosis or is merely a symptom of the disease.

IBSA Group and Granata Bio announces first patient screened in pivotal PROGRESS clinical trial of Progesterone-IBSA

Retrieved on: 
Wednesday, October 19, 2022
Reproductive health, Disease, Centers for Disease Control and Prevention timeline, Woman, Vaginal bleeding, Blastocyst, Luteal phase, Progesterone, Patient, ART, Malignancy, Multimedia, IBSA, Transfer, Rest, Plasma protein binding, III, Marketing, Health, CEO, PROGRESS, Breast, Ageing, Safety, Clinical trial, Infertility, Liver, Center, Pregnancy, Thrombophlebitis, Apoplexy, Prevention, Pharmaceutical industry, Birth control

BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).

Key Points: 
  • BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).
  • The study is expected to enroll about 680 patients between the ages of 35-42 years old.
  • "The IBSA Group is excited for this key milestone in development of our subcutaneous progesterone in the United States.
  • IBSA Group, headquartered in Lugano, Switzerland, is a leader in reproductive health and has a diversified product portfolio of prescription drugs and biologics.

Proov® Announces The Release of its New Study, Showing Sustained Elevated PdG Levels Increase Clinical Pregnancy Rates by 75%

Retrieved on: 
Thursday, September 29, 2022
Time, Journal, Woman, Risk, FDA, PDG, Ovulation, Luteal phase, Fertility, LH, Gynaecology, CEO, Infertility, Progesterone, Obstetrics, Research, Urine, MFB, Birth control

BOULDER, Colo., Sept. 29, 2022   /PRNewswire-PRWeb/ -- Proov, makers of the first and only FDA-cleared PdG-test and the first full cycle tracking kit, is announcing first of its kind findings that should help inform the medical community and American women surrounding the role of PdG.

Key Points: 
  • Proov's study has shown that Positive PdG cycles are associated with increased pregnancy rates and lower odds of a first-trimester pregnancy loss.
  • This demonstrates an increased need for consideration for luteal phase support with progesterone or ovulation induction in women with negative PdG cycles and that this can be of benefit.
  • Proov has always focused its time, research, and diagnostic development on what happens after ovulation.
  • MFB Fertility, Inc. developed Proov, an at-home PdG test that measures the presence of progesterone metabolite PdG in urine to help a woman confirm that she has ovulated successfully.